Medivation drug shows positive results in Alzheimer’s patients; shares up 3% in pre-market
Biopharmaceutical company Medivation Inc. (Nasdaq:MDVN) said after Thursday’s close it had positive results in its testing of the drug Dimebon in the treatment of Alzheimer’s disease. The results showed that patients who received the treatment who had mild-to-moderate Alzheimer’s showed statistically significant improvements compared to those who took the placebo. The San Francisco-based company said patients saw benefits from the drug after six months and continued to improve up to a year.
In today’s pre-market trading, shares of Medivation are mostly flat, up $0.54 to $19.15. During the past 52 weeks, shares have ranged from $11.53 to $25.06.
For detailed price information and recent news stories about Medivation Inc., click MDVN.
